The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers

What Was Tested

The paper reports a study of Bradykinin, published as a randomized controlled trial.

Bradykinin 1 receptor (B1R) signalling pathways may be involved in the inflammatory pathophysiology of chronic obstructive pulmonary disease (COPD).

The study was registered on January 14, 2016 at ClinicalTrials.gov (NCT02657408).

Who Took Part

Twenty-four hours later, TIRM MRI was performed, then BAL and biopsies were collected from the challenged segments.

Other endpoints included assessment of safety, biomarkers in BAL (e.g. interleukin-8 [IL-8], albumin and total protein), B1R expression in lung biopsies and TIRM score by MRI as a measure for the extent of pulmonary oedema.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Bradykinin group a baseline to be compared against.

The Bradykinin group and the comparison group ran side by side rather than switching.

At day 21, turbo-inversion recovery magnitude magnetic resonance imaging (TIRM MRI) was performed.

In BAL samples, cells were differentiated for neutrophil numbers as the primary endpoint.

What Was Measured

Topics PubMed links to this paper include Lipopolysaccharides, Interleukin-8, Bradykinin, Smokers, Pneumonia, Inflammation and Bronchoalveolar Lavage Fluid.

Author keywords: Bradykinin 1 receptor inhibitor, Bronchoscopy, Clinical proof-of-concept, Experimental lung inflammation and Randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Pulmonary pharmacology & therapeutics), a journal based in England.

More context: the Bradykinin compound page, all human trials.